Lilly's Zepbound Surpasses Novo's Wegovy in Pivotal Head-to-Head Trial

In a groundbreaking development within the realm of obesity treatment, Eli Lilly's Zepbound has emerged victorious over Novo Nordisk's Wegovy in a head-to-head clinical trial. This significant study marks a notable shift in the competitive landscape of weight management therapies, paving the way for new choices for patients struggling with obesity.

Continue reading